EP2928470A4 - Thienopyridine derivatives for the treatment and prevention of dengue virus infections - Google Patents

Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Info

Publication number
EP2928470A4
EP2928470A4 EP13859644.0A EP13859644A EP2928470A4 EP 2928470 A4 EP2928470 A4 EP 2928470A4 EP 13859644 A EP13859644 A EP 13859644A EP 2928470 A4 EP2928470 A4 EP 2928470A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
dengue virus
virus infections
thienopyridine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13859644.0A
Other languages
German (de)
French (fr)
Other versions
EP2928470A1 (en
Inventor
Dongcheng Dai
James R Burgeson
Shanthakumar R Tyavanagimatt
Chelsea M Byrd
Dennis E Hruby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/708,224 external-priority patent/US20130129677A1/en
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of EP2928470A1 publication Critical patent/EP2928470A1/en
Publication of EP2928470A4 publication Critical patent/EP2928470A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13859644.0A 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections Withdrawn EP2928470A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/708,224 US20130129677A1 (en) 2009-02-27 2012-12-07 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
PCT/US2013/073449 WO2014089378A1 (en) 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Publications (2)

Publication Number Publication Date
EP2928470A1 EP2928470A1 (en) 2015-10-14
EP2928470A4 true EP2928470A4 (en) 2015-12-16

Family

ID=50884015

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13859644.0A Withdrawn EP2928470A4 (en) 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Country Status (4)

Country Link
EP (1) EP2928470A4 (en)
JP (1) JP2016501883A (en)
CA (1) CA2893318A1 (en)
WO (1) WO2014089378A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418635A (en) * 2015-12-25 2016-03-23 上海应用技术学院 Synthesis method of thienopyridine medical intermediate
CN105769866B (en) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 A kind of purposes of compound in platelet concentration medicine is increased
CN105832734B (en) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 A kind of purposes of compound in platelet concentration medicine is increased
US10689394B2 (en) 2016-06-14 2020-06-23 The University Of Tokyo Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
AU2018361971A1 (en) * 2017-11-03 2020-06-04 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
US20210230179A1 (en) * 2018-06-06 2021-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses
US20220332720A1 (en) * 2019-08-21 2022-10-20 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
CN111072463A (en) * 2019-12-03 2020-04-28 辽宁凯莱英医药化学有限公司 Continuous synthesis method of 4-ethoxy-1, 1, 1-trifluoro-3-butene-2-one
WO2021108999A1 (en) * 2019-12-03 2021-06-10 辽宁凯莱英医药化学有限公司 Method for continuous synthesis of 4-ethoxy-1,1,1-trifluoro-3-buten-2-one
WO2021250231A1 (en) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Thienopyridine derivatives for use in the treatment of coronavirus infection
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151544A1 (en) * 2000-04-27 2002-10-17 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006068618A1 (en) * 2004-12-23 2006-06-29 Astrazeneca Ab New compounds
JP2006298909A (en) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd Pharmaceutical composition
WO2007136776A2 (en) * 2006-05-17 2007-11-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pyrimidine low molecular weight ligands for modulating hormone receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3533095A (en) * 1994-09-22 1996-04-09 Rational Drug Design Laboratories Arylthiadiazole derivative and antiviral agent containing the same
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
AR048669A1 (en) * 2004-03-03 2006-05-17 Syngenta Ltd BISAMIDE BICYCLE DERIVATIVES
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
AP3069A (en) * 2009-02-27 2014-12-31 Siga Technologies Inc Thienopyridine derivatives for the treatment and prvention of dengue virus infection
US8785499B2 (en) * 2009-07-10 2014-07-22 University Of Maryland, Baltimore Targeting NAD biosynthesis in bacterial pathogens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151544A1 (en) * 2000-04-27 2002-10-17 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006068618A1 (en) * 2004-12-23 2006-06-29 Astrazeneca Ab New compounds
JP2006298909A (en) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd Pharmaceutical composition
WO2007136776A2 (en) * 2006-05-17 2007-11-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pyrimidine low molecular weight ligands for modulating hormone receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014089378A1 *

Also Published As

Publication number Publication date
JP2016501883A (en) 2016-01-21
EP2928470A1 (en) 2015-10-14
CA2893318A1 (en) 2014-06-12
WO2014089378A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
EP2400845A4 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
EP2928470A4 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IL244431A0 (en) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
ZA201502238B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IL236221A (en) Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases
IL236989A0 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
IL237173B (en) Methods for the treatment of hepatitis b and hepatitis d infections
HUE044216T2 (en) Chitin or derivatives thereof for the prevention and/or treatment of parasitoses
EP2869821A4 (en) Compositions and methods for treating and inhibiting viral infections
PL3082845T3 (en) Methods and compositions for treatment of peripheral neuropathies
IL238126A0 (en) Formulations for the treatment and prevention of obesity
IL246286A0 (en) Pharmaceutical preparation for preventing and treating progressive myopia
ZA201501601B (en) Virus purification and formulation process
EP2838526A4 (en) Materials and methods for prevention and treatment of viral infections
EP3079657B8 (en) Preparation for prevention and/or treatment of peri-implantitis
PT2838903T (en) Methods and compositions for treating viral infections
EP2826486A4 (en) Agent for the treatment of hepatitis c virus
AP2015008726A0 (en) Low-glycerin-formulations for hiv treatment and prevention
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses
AU2012905097A0 (en) Agents and methods for inhibiting virus infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BYRD, CHELSEA, M.

Inventor name: BURGESON, JAMES, R.

Inventor name: HRUBY, DENNIS, E.

Inventor name: DAI, DONGCHENG

Inventor name: TYAVANAGIMATT, SHANTHAKUMAR, R.

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151113

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4365 20060101AFI20151109BHEP

Ipc: A61K 31/4375 20060101ALI20151109BHEP

Ipc: C07D 495/14 20060101ALI20151109BHEP

Ipc: C07D 495/06 20060101ALI20151109BHEP

Ipc: C07D 495/22 20060101ALI20151109BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TYAVANAGIMATT, SHANTHAKUMAR, R.

Inventor name: BURGESON, JAMES, R.

Inventor name: HRUBY, DENNIS, E.

Inventor name: BYRD, CHELSEA, M.

Inventor name: DAI, DONGCHENG

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170713

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171124